Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

Taylor PT, Haverstick D.

J Natl Cancer Inst. 2005 Jan 19;97(2):151; author reply 152. No abstract available.

2.

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J.

J Natl Cancer Inst. 2004 Mar 17;96(6):487-8. No abstract available.

3.

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.

Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB.

J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5. No abstract available.

4.
5.

Human monoclonal antibody for ovarian clear cell carcinoma-2, a human monoclonal antibody with antitumor activity against ovarian cancer cells that recognizes CA125-like antigen.

Suzuki N, Tamada Y, Shigirahara K, Suzuki A, Susumu N, Ishida I, Aoki D.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):996-1006. Epub 2007 Nov 20.

PMID:
18028379
6.

[Ovarian cancer].

Finnish Gynecological Association.

Duodecim. 2001;117(22):2318-32. Finnish. No abstract available.

PMID:
12183965
7.

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.

Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M.

Int J Gynecol Cancer. 2005 Sep-Oct;15(5):679-91.

PMID:
16174214
8.

CA 125: Value or addiction?

Goldman PA.

Cancer. 2010 Jun 15;116(12):2854-5. doi: 10.1002/cncr.25185. No abstract available.

9.

Monoclonal antibodies in the treatment of ovarian cancer.

Markowska J.

Eur J Gynaecol Oncol. 2003;24(1):7-11.

PMID:
12691308
10.

[Adnexal tumors after surgical treatment of colorectal cancer].

Gottwald L, Korczyński J, Góra E, Bieńkiewicz A.

Ginekol Pol. 2008 Apr;79(4):259-63. Polish.

PMID:
18592863
11.

Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody.

Oei AL, Sweep FC, Massuger LF, Olthaar AJ, Thomas CM.

Gynecol Oncol. 2008 May;109(2):199-202. doi: 10.1016/j.ygyno.2008.01.025. Epub 2008 Mar 4.

PMID:
18304620
12.

Antitumor activity of specific immunotherapy with mucin containing CA 125 antigen in mice with CaO 1 ovarian carcinoma.

Amandzholov BS, Sitdikova SM, Lebedin YS, Chukanov SV, Toptygin AY, Manzyuk LV, Donenko FV.

Bull Exp Biol Med. 2000 Apr;129(4):383-5.

PMID:
10977928
13.

Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination.

Chechlinska M, Kaminska J, Markowska J, Kramar A, Steffen J.

Int J Biol Markers. 2007 Jul-Sep;22(3):172-80.

PMID:
17922459
14.

[Review and revision of guidelines for ovarian cancer treatment in Japan].

Kigawa J, Katabuchi H, Yaegashi N.

Gan To Kagaku Ryoho. 2010 Apr;37(4):617-9. Japanese.

PMID:
20414017
15.

Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.

Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, van der Zee AG, Daemen T, Nijman HW, Kast WM.

Clin Cancer Res. 2007 Apr 15;13(8):2385-91.

16.

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).

Oei AL, Sweep FC, Thomas CM, Boerman OC, Massuger LF.

Int J Oncol. 2008 Jun;32(6):1145-57. Review.

PMID:
18497976
17.

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Schultes BC, Smith LM, Nicodemus CF.

Clin Cancer Res. 2007 Jul 1;13(13):4026; author reply 4026-7. No abstract available.

18.

Guidelines for referral of the patient with an adnexal mass.

Gostout BS, Brewer MA.

Clin Obstet Gynecol. 2006 Sep;49(3):448-58. Review.

PMID:
16885652
19.
20.

CASE 2. Meningeal metastases from ovarian carcinoma.

Mukhopadhyay S, Mukhopadhyay S, El-Zammar O, Khurana KK, Graziano SL.

J Clin Oncol. 2006 Feb 20;24(6):1010-1. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk